# Obsidian Therapeutics (OBX) — Analyst Forecast

OBX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/obx/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 3 | 0 | 0 | 3 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $32.00 | $39.00 | $43.00 | 3 |

Last price $12.20 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Sep 22, 2026 | Leerink Partners | Initiated Coverage | Outperform | $32.00 |
| Sep 9, 2026 | William Blair | Initiated Coverage | Outperform | — |
| Aug 18, 2026 | LifeSci Capital | Initiated Coverage | Outperform | $43.00 |
| Aug 5, 2026 | Piper Sandler | Initiated Coverage | Overweight | $42.00 |

## Frequently Asked Questions

### What is the price target for OBX stock?

The average 12-month analyst price target for Obsidian Therapeutics (OBX) is $39.00, with a high estimate of $43.00 and a low of $32.00, across 3 analysts.

### Is OBX a buy, sell, or hold?

Analysts covering Obsidian Therapeutics currently average a Buy rating: 3 buy, 0 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for OBX?

The average price target of $39.00 implies 219.67% upside from the last price of $12.20.

### What is the latest analyst rating on OBX?

On Sep 22, 2026, Leerink Partners initiated coverage of Obsidian Therapeutics at Outperform with a price target of $32.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).